Singapore-based digital health startup Mesh Bio has raised $1.8 million in a seed funding round led by deep tech investors Elev8.vc and Seeds Capital, the investment arm of Enterprise Singapore.
Citrine Capital and Tael Partners also participated in the funding round that will finance the rollout of the startup’s predictive analytics and clinical workflow automation solution DARA in Southeast Asia and Hong Kong.
Founded in 2018, Mesh Bio develops clinical decision support analytics and automation solutions for the management of chronic diseases, such as cardiovascular illnesses. According to Deloitte, predictive analytics will play a central role in improving the health and reducing mortality rates across age groups.
The startup’s founder, Andrew Wu, said chronic diseases are increasing in Asia. For instance, diabetes prevalence in Malaysia is the highest in the region at 16.8% compared to 14.2% in Singapore and 8.3% in Thailand.
The situation, Wu stressed, is compounded by the lack of specialists forcing general practitioners – lacking training in endocrinology – to manage these challenging patient cases.
“Our vision is to deliver cutting-edge digital solutions to address challenges in patient management and rising chronic diseases in the region,” Wu said.
The firm was the first Asian startup to be selected for the prestigious Startup Creasphere digital health acceleration program by Roche Diagnostics and Plug and Play.
South Africa Today
Read more at VolaNews
